Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Hypersensitivity Reaction

Free Subscription Articles published in Eur J Dermatol Retrieve available abstracts of 90 articles: HTML format

Single Articles

February 2024
1. FUKUDA H, Aoki S, Harada Y, Matsumoto C, et al
   A case of acute generalized exanthematous pustulosis caused by eperisone hydrochloride.
   Eur J Dermatol. 2024;34:97-98.
   PubMed    
   
   
   
2. OUNI B, Mansour K, Sassi M, Sriha B, et al
   Silodosin-induced leukocytoclastic vasculitis: a first case report.
   Eur J Dermatol. 2024;34:92-93.
   PubMed    
   
   
   
3. GIMENEZ-ARNAU AM, Salman A, Podder I
   Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review.
   Eur J Dermatol. 2024;34:3-12.
   PubMed     Abstract available
   
   
   December 2023
4. DE GREEF A, Ghislain PD, Baeck M
   Prolonged real-life experience with baricitinib in patients with moderate-to-severe atopic dermatitis.
   Eur J Dermatol. 2023;33:707-709.
   PubMed    
   
   
   
5. NISHIYORI R, Sakai T, Nishida H, Hatano Y, et al
   An unusual case of immediate and delayed hypersensitivity to wasp stings.
   Eur J Dermatol. 2023;33:701-703.
   PubMed    
   
   
   
6. TSAI YC, Tsai TF
   Successful treatment of atopic dermatitis by switching from upadacitinib to abrocitinib: a case report.
   Eur J Dermatol. 2023;33:699-701.
   PubMed    
   
   
   
7. MIYAWAKI K, Nakashima C, Otsuka A
   Real-world effectiveness and safety of nemolizumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study.
   Eur J Dermatol. 2023;33:691-692.
   PubMed    
   
   
   
8. LAMOLET M, Barbarin C, Renaud O, Sahin Y, et al
   Acceleration of cutaneous T-cell lymphoma mistaken for atopic dermatitis following JAK inhibitor use.
   Eur J Dermatol. 2023;33:686-687.
   PubMed    
   
   
   
9. COHEN E, Lheure C, Ingen-Housz-Oro S, Hotz C, et al
   Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients.
   Eur J Dermatol. 2023;33:680-685.
   PubMed     Abstract available
   
   
   October 2023
10. MURRAY C, Ridge K, Conlon N
    Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria.
    Eur J Dermatol. 2023;33:561-562.
    PubMed    
    
    
    
11. NISHITANI K, Nakajima S, Miyake T, Kaku Y, et al
    Cutaneous sarcoidosis concomitant with xanthoma on the face.
    Eur J Dermatol. 2023;33:559-561.
    PubMed    
    
    
    
12. KAMADA H, Arakawa N, Fukui R, Tanji T, et al
    Nemolizumab-induced drug eruption in a 46-year-old male patient with atopic dermatitis.
    Eur J Dermatol. 2023;33:558-559.
    PubMed    
    
    
    
13. FIGUEIREDO C, Matos AL, Cardoso JC
    Bilateral periorbital swelling as the presenting manifestation of recurrent breast carcinoma.
    Eur J Dermatol. 2023;33:551-553.
    PubMed    
    
    
    
14. ZHENG H, Chen Y, Xu Y, Deng X, et al
    Efficacy and safety of abrocitinib for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis: update of a living systematic review and meta-analysis.
    Eur J Dermatol. 2023;33:530-543.
    PubMed     Abstract available
    
    
    
15. LUGER T, Chu CY, Elgendy A, Ibrahim SBBK, et al
    Pimecrolimus 1% cream for mild-to-moderate atopic dermatitis: a systematic review and meta-analysis with a focus on children and sensitive skin areas.
    Eur J Dermatol. 2023;33:474-486.
    PubMed     Abstract available
    
    
    August 2023
16. YAMADA M, Furuta M, Fujimoto N
    Erythema multiforme major induced by tramadol.
    Eur J Dermatol. 2023;33:437-439.
    PubMed    
    
    
    
17. TOYOSHIMA M, Nakaoji K, Hamada K, Yamanaka A, et al
    Analysis of skin aging patterns using a facial imaging system in patients with atopic dermatitis.
    Eur J Dermatol. 2023;33:383-393.
    PubMed     Abstract available
    
    
    
18. ESCALANTE A, Serra-Baldrich E
    Pathogenic mechanisms underlying itch in atopic dermatitis: the emerging role of neuroimmune interactions.
    Eur J Dermatol. 2023;33:343-349.
    PubMed     Abstract available
    
    
    
19. YU YY, Li JX, Zeng YP
    Scientific landscape and trend analysis of chronic urticaria: a two-decade bibliometric review.
    Eur J Dermatol. 2023;33:404-412.
    PubMed     Abstract available
    
    
    
20. UOZUMI T, Serizawa N, Hagino T, Morita T, et al
    Dietary habits in Japanese patients with bullous pemphigoid: low intake of retinol.
    Eur J Dermatol. 2023;33:394-403.
    PubMed     Abstract available
    
    
    April 2023
21. KOMAKI R, Miyagaki T, Okano T, Takeuchi S, et al
    Decreased serum placental growth factor levels in adult atopic dermatitis: a preliminary study.
    Eur J Dermatol. 2023;33:185-186.
    PubMed    
    
    
    
22. MATOS PR, Nogueira A, Gomes N, Pedrosa A, et al
    Acute generalized exanthematous pustulosis secondary to mianserin with liver involvement.
    Eur J Dermatol. 2023;33:172-174.
    PubMed    
    
    
    
23. DEYDIER N, Salvado M, Planes M, Misery L, et al
    Atopic dermatitis in 15q24 microdeletion syndrome: a social media study.
    Eur J Dermatol. 2023;33:157-159.
    PubMed     Abstract available
    
    
    
24. PATSATSI A, Vakirlis E, Kanelleas A, Stefanaki I, et al
    Effect of a novel "emollient plus" formulation on mild-to-severe atopic dermatitis and other dry skin-related diseases as monotherapy or adjunctive therapy: an observational study on efficacy, tolerance and quality of life in adult patients.
    Eur J Dermatol. 2023;33:137-146.
    PubMed     Abstract available
    
    
    
25. LI JX, Zeng YP
    Research interest in the usage of dupilumab for atopic dermatitis: a bibliometric analysis.
    Eur J Dermatol. 2023;33:87-100.
    PubMed     Abstract available
    
    
    February 2023
26. MOSNIER A, Vocanson M, Lefevre MA
    Molecular profiling of skin test-induced inflammation to support the clinical diagnosis of delayed drug hypersensitivity reaction.
    Eur J Dermatol. 2023;33:64-66.
    PubMed    
    
    
    
27. LAMOUROUX C, Bertolotti-Potachin L, Charbotel B, Nosbaum A, et al
    Allergic contact dermatitis to diclofenac gel due to propylene glycol sensitization: usefulness of repeated open application tests to determine safer alternatives.
    Eur J Dermatol. 2023;33:42-43.
    PubMed    
    
    
    November 2022
28. ELDANI C, Darrigade AS, Beylot-Barry M, Jullie ML, et al
    Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as "toxic epidermal necrolysis-like".
    Eur J Dermatol. 2022;32:805-807.
    PubMed    
    
    
    
29. KOSAKA K, Uchiyama A, Ishikawa M, Watanabe G, et al
    Real-world effectiveness and safety of upadacitinib in Japanese patients with atopic dermatitis: a two-centre retrospective study.
    Eur J Dermatol. 2022;32:800-802.
    PubMed    
    
    
    
30. KIM J, Choi S, Choi S, Lee YI, et al
    Contact hypersensitivity and Demodex mite infestation in patients with rosacea: a retrospective cohort analysis.
    Eur J Dermatol. 2022;32:716-723.
    PubMed     Abstract available
    
    
    
31. SALOMON G, Giordano-Labadie F
    Surfactant irritations and allergies.
    Eur J Dermatol. 2022;32:677-681.
    PubMed     Abstract available
    
    
    September 2022
32. HONDA R, Suenaga A, Nakahara T, Shibata-Kikuchi S, et al
    Atopic dermatitis refractory to dupilumab but markedly responsive to baricitinib.
    Eur J Dermatol. 2022;32:649-650.
    PubMed    
    
    
    
33. STEFANOU G, Gregoriou S, Kontodimas S, Sfaelos K, et al
    Prevalence of adult self-reported atopic dermatitis in Greece: results from a nationwide survey.
    Eur J Dermatol. 2022;32:597-606.
    PubMed     Abstract available
    
    
    
34. MELE-NINOT G, Serra-Baldrich E, Spertino J, Guilarte M, et al
    Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?
    Eur J Dermatol. 2022;32:629-631.
    PubMed     Abstract available
    
    
    
35. SALONEN J, Remitz A, Salonen J, Lauerma A, et al
    Allergic conjunctivitis: a risk factor for recurrent herpes simplex virus infections in patients with atopic dermatitis.
    Eur J Dermatol. 2022;32:607-614.
    PubMed     Abstract available
    
    
    
36. TIOTIU A, Jaussaud R
    Successful treatment with omalizumab for cold urticaria in a patient with chronic hepatitis C virus infection.
    Eur J Dermatol. 2022;32:640-641.
    PubMed    
    
    
    
37. TETART F, Gonde H, Hervouet C
    Do generic drugs cause hypersensitivity?
    Eur J Dermatol. 2022;32:571-576.
    PubMed     Abstract available
    
    
    July 2022
38. PIOTIN A, Hacard F, Crumbach L, Nicolas JF, et al
    Anaphylaxis to chlorhexidine after taking oral medication
    Eur J Dermatol. 2022;32:551-553.
    PubMed    
    
    
    
39. BRAUN C, Patra V, Lina G, Nicolas JF, et al
    The role of skin dysbiosis in atopic dermatitis
    Eur J Dermatol. 2022;32:439-444.
    PubMed     Abstract available
    
    
    
40. WOLLENBERG A, Lio P, Kleyn E, Bissonnette R, et al
    Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials
    Eur J Dermatol. 2022;32:522-529.
    PubMed     Abstract available
    
    
    
41. SERRANO ORDONEZ A, Lopez Riquelme I, Perea Polak A
    sQuiz your knowledge! Persistent unilateral facial and lip swelling
    Eur J Dermatol. 2022;32:562-563.
    PubMed    
    
    
    
42. KITAYAMA S, Makino T, Kataoka K, Mori S, et al
    Valacyclovir-induced drug reaction with eosinophilia and systemic symptoms
    Eur J Dermatol. 2022;32:538-539.
    PubMed    
    
    
    
43. MARTINEZ-SAGUER I, Dominas N, Straben U, Greve J, et al
    Patients with hereditary angioedema and their treatment patterns in Germany: a Delphi consensus study
    Eur J Dermatol. 2022;32:487-494.
    PubMed     Abstract available
    
    
    
44. PANKAKOSKI A, Kluger N, Sintonen H, Panelius J, et al
    Clinical manifestations and comorbidities of pemphigus: a retrospective case-control study in southern Finland
    Eur J Dermatol. 2022;32:480-486.
    PubMed     Abstract available
    
    
    May 2022
45. LEFEVRE MA
    "Prick or treat": a case of systemic reaction during intradermal tests with beta-lactams
    Eur J Dermatol. 2022;32:426-428.
    PubMed    
    
    
    
46. FUJISHIMA C, Munemoto S, Hioki C, Sasaki H, et al
    Successful dupilumab therapy for atopic dermatitis in a patient with X-linked agammaglobulinaemia
    Eur J Dermatol. 2022;32:416-417.
    PubMed    
    
    
    
47. NAKAGAWA M, Hanada M, Amano H
    Allergic contact stomatitis caused by (meth)acrylates following sensitization by artificial nails, 20 years previously
    Eur J Dermatol. 2022;32:413-415.
    PubMed    
    
    
    
48. ROLO DE MATOS P, Nogueira A, Gomes N, Costa C, et al
    Rare presentation of Wells syndrome mimicking angioedema: a case report
    Eur J Dermatol. 2022;32:411-413.
    PubMed    
    
    
    
49. ULDAHL A, Sterner T, Bruze M, Dahlin J, et al
    Atopy patch testing and associations with atopic conditions and specific IgE tests: a population-based study in adolescents
    Eur J Dermatol. 2022;32:384-393.
    PubMed     Abstract available
    
    
    
50. GUILLON C, Meziani M, Abdelli S, Sigaudo Roussel D, et al
    The aryl hydrocarbon receptor pathway plays a central role in the cutaneous response to pollutants
    Eur J Dermatol. 2022;32:305-311.
    PubMed     Abstract available
    
    
    April 2022
51. SCHUSTER B, Ziehfreund S, Schielein MC, Tizek L, et al
    Adding happiness to complement the Dermatology Quality of Life Index in psoriasis and atopic dermatitis healthcare: a cross-sectional study
    Eur J Dermatol. 2022;32:220-226.
    PubMed     Abstract available
    
    
    
52. MASUDA K, Delozier AM, Kolodsick J, Buchanan A, et al
    Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysi
    Eur J Dermatol. 2022;32:237-243.
    PubMed     Abstract available
    
    
    
53. STEFANIAK AA, Knecht K, Matusiak L
    sQuiz your knowledge! Non-pruritic chronic urticaria and recurrent episodes of fever
    Eur J Dermatol. 2022;32:300-301.
    PubMed    
    
    
    February 2022
54. VAN HALEWIJN KF, Lahnstein T, Bohnen AM, Van Den Berg PJ, et al
    Recommendations for emollients, bathing and topical corticosteroids for the treatment of atopic dermatitis: a systematic review of guidelines.
    Eur J Dermatol. 2022 Feb 21. pii: ejd.2022.4197. doi: 10.1684/ejd.2022.4197.
    PubMed     Abstract available
    
    
    
55. NADA HR, Rashed LA, Shehada J, Mostafa PIN, et al
    Phosphodiesterase 4 (PDE4) gene expression in atopic dermatitis patients, before and after treatment with topical mometasone cream.
    Eur J Dermatol. 2022 Feb 15. pii: ejd.2022.4194. doi: 10.1684/ejd.2022.4194.
    PubMed     Abstract available
    
    
    
56. ESCURE G, Nudel M, Terriou L, Farhat MM, et al
    Tolerance of bradykinin-releasing drugs in patients with acquired C1 inhibitor deficiency: a case series and review of the literature.
    Eur J Dermatol. 2022;32:49-55.
    PubMed    
    
    
    January 2022
57. LEFEVRE MA, Mosnier A
    A case of paracetamol-induced nonpigmented fixed drug eruption confirmed by a lymphocyte transformation test.
    Eur J Dermatol. 2022;32:154-156.
    PubMed    
    
    
    
58. SHEN X, Zhang W, Li X, Lu H, et al
    Association between serum IgG and Henoch-Schonlein purpura with renal involvement in children: a cross-sectional study.
    Eur J Dermatol. 2022;32:132-134.
    PubMed    
    
    
    December 2021
59. SALAVA A, Perala M, Juppo M, Pelkonen AS, et al
    Effective treatment of atopic dermatitis in small children significantly improves the quality of life of patients and their families.
    Eur J Dermatol. 2021 Dec 21. pii: ejd.2021.4169. doi: 10.1684/ejd.2021.4169.
    PubMed     Abstract available
    
    
    
60. EGEBERG A, Anderson P, Piercy J, Massey L, et al
    Symptom burden of patients with moderate-to-severe atopic dermatitis.
    Eur J Dermatol. 2021 Dec 21. pii: ejd.2021.4166. doi: 10.1684/ejd.2021.4166.
    PubMed     Abstract available
    
    
    
61. LORET L, Ninclaus V, Dendooven A, Lapeere H, et al
    Canalicular stenosis associated with dupilumab treatment for atopic dermatitis.
    Eur J Dermatol. 2021 Dec 17. pii: ejd.2021.4180. doi: 10.1684/ejd.2021.4180.
    PubMed    
    
    
    
62. CHESTER J, Kaleci S, Liberati S, Alicandro T, et al
    Atopic dermatitis associated with autoimmune, cardiovascular and mental health comorbidities: a systematic review and meta-analysis.
    Eur J Dermatol. 2021 Dec 15. pii: ejd.2021.4168. doi: 10.1684/ejd.2021.4168.
    PubMed     Abstract available
    
    
    
63. LEFEVRE MA, Mohme S, Alband N, Nogueira M, et al
    Journal club: New small molecules for atopic dermatitis management.
    Eur J Dermatol. 2021;31:849-852.
    PubMed    
    
    
    
64. TRAIDL S, Heratizadeh A, Werfel T, Dressler C, et al
    Online survey to identify current challenges in atopic dermatitis management and guideline implementation in German-speaking countries.
    Eur J Dermatol. 2021;31:806-812.
    PubMed     Abstract available
    
    
    
65. ROVATI C, Rossi M, Gelmetti A, Tomasi C, et al
    Impact of the COVID-19 pandemic and lockdown on the clinical response to dupilumab treatment and the psychological status of non-infected atopic patients.
    Eur J Dermatol. 2021;31:736-740.
    PubMed     Abstract available
    
    
    
66. RAVAL NS, Snowden CK, De Monnin KS, Yokoyama CC, et al
    Scarring alopecia developing after mogamulizumab-associated rash.
    Eur J Dermatol. 2021;31:841-843.
    PubMed    
    
    
    
67. SUKAKUL T, Svedman C, Dahlin J, Bergendorff O, et al
    Simultaneous positive patch test reactions to neomycin and low-molecular-weight heparins: possible cross-reaction?
    Eur J Dermatol. 2021;31:741-743.
    PubMed     Abstract available
    
    
    October 2021
68. KURIHARA K, Fujiyama T, Tokura Y, Honda T, et al
    Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment.
    Eur J Dermatol. 2021 Oct 26. pii: ejd.2021.4140. doi: 10.1684/ejd.2021.4140.
    PubMed    
    
    
    
69. KHELLAF L, Cosserat J, Calas A, Brasme H, et al
    Unusual neurological and cardiac complications of drug reaction with eosinophilia and systemic symptoms syndrome: a case report.
    Eur J Dermatol. 2021;31:652-654.
    PubMed    
    
    
    
70. FANG YH, Wei KC, Yu MS
    Improvement of erythema elevatum diutinum refractory to dapsone following treatment for underlying multiple myeloma.
    Eur J Dermatol. 2021;31:655-657.
    PubMed    
    
    
    August 2021
71. INGEN-HOUSZ-ORO S, Staumont-Salle D, Palladini A, Ferries L, et al
    Immunosuppressants as steroid-sparing agents for chronic DRESS: four cases.
    Eur J Dermatol. 2021;31:576-577.
    PubMed    
    
    
    June 2021
72. LEFEVRE MA, Nosbaum A
    Dermpath and Clinic: How to manage adverse reactions to biological agents.
    Eur J Dermatol. 2021;31:426-427.
    PubMed    
    
    
    
73. CUI Y, Shi J, Wang C, Vinturache A, et al
    Therapeutic plasma exchange combined with continuous venovenous hemofiltration in a series of pediatric patients with toxic epidermal necrolysis.
    Eur J Dermatol. 2021;31:413-415.
    PubMed    
    
    
    
74. WATABE D, Amano H
    TNF-alpha inhibitor-induced paradoxical psoriasis and erythema nodosum in a patient with ankylosing spondylitis.
    Eur J Dermatol. 2021;31:412-413.
    PubMed    
    
    
    
75. PERRON E, Viarnaud A, Marciano L, Karkouche R, et al
    Clinical and histological features of fixed drug eruption: a single-centre series of 73 cases with comparison between bullous and non-bullous forms.
    Eur J Dermatol. 2021;31:372-380.
    PubMed     Abstract available
    
    
    
76. SUGINO H, Nakamura M
    Mild hypertrichosis in both upper arms around dupilumab injection sites.
    Eur J Dermatol. 2021;31:420-421.
    PubMed    
    
    
    April 2021
77. MORIMOTO H, Fukuchi K, Ogura Y, Ohtsuka M, et al
    Development of lichen planus following benralizumab treatment.
    Eur J Dermatol. 2021 Apr 2. pii: ejd.2021.3995. doi: 10.1684/ejd.2021.3995.
    PubMed    
    
    
    
78. GIORDANO-LABADIE F, Becherel PA, Pralong P, Outtas O, et al
    Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Eur J Dermatol. 2021;31:217-224.
    PubMed     Abstract available
    
    
    March 2021
79. KIRSTEN N, Mohr N, Maul JT, Augustin M, et al
    Incidence of atopic conditions in people with psoriasis: a population-based analysis.
    Eur J Dermatol. 2021 Mar 1. pii: ejd.2021.3963. doi: 10.1684/ejd.2021.3963.
    PubMed     Abstract available
    
    
    February 2021
80. BELBEZIER A, Boccon-Gibod I, Bouillet L
    Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
    Eur J Dermatol. 2021;31:86-87.
    PubMed    
    
    
    
81. KOMATSU-FUJII T, Ogawa M, Nonoyama S, Fukumoto T, et al
    Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1(R)) after nivolumab discontinuation.
    Eur J Dermatol. 2021;31:98-99.
    PubMed    
    
    
    
82. KUMANO Y, Nagai A, Sugiura K
    Erythro-papular type drug eruption caused by fosravuconazole L-lysine ethanolate.
    Eur J Dermatol. 2021;31:90-91.
    PubMed    
    
    
    
83. UGAJIN T, Namiki T, Yokozeki H
    A case of prurigo caused by hair dye containing p-phenylenediamine: histopathological findings.
    Eur J Dermatol. 2021;31:103-104.
    PubMed    
    
    
    
84. MAKIHARA-INUKAI M, Takeichi T, Ogawa-Momohara M, Muro Y, et al
    Morphea in a Crohn's disease patient undergoing ustekinumab treatment.
    Eur J Dermatol. 2021;31:96-97.
    PubMed    
    
    
    
85. FAUCON C, Bernigaud C, Sbidian E, Hue S, et al
    Essential oils as potential triggers for bullous pemphigoid? A report of two patients.
    Eur J Dermatol. 2021;31:92-93.
    PubMed    
    
    
    
86. HAYAMA K, Fujita H, Asai-Sato M, Kawana K, et al
    Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer.
    Eur J Dermatol. 2021;31:100-101.
    PubMed    
    
    
    January 2021
87. NAGASAWA Y, Iinuma S, Fujii M, Kanno K, et al
    Dasatinib-induced panniculitis in a patient with chronic myeloid leukaemia.
    Eur J Dermatol. 2021 Jan 25. pii: ejd.2020.3946. doi: 10.1684/ejd.2020.3946.
    PubMed    
    
    
    
88. COSTEDOAT I, Vergara R, Dousset L, Gerard E, et al
    Drug-induced bullous lichenoid eruption: a side effect of nivolumab triggered by the TLR agonist imiquimod.
    Eur J Dermatol. 2021 Jan 15. pii: ejd.2020.3951. doi: 10.1684/ejd.2020.3951.
    PubMed    
    
    
    December 2020
89. DANSET M, Hacard F, Jaulent C, Nosbaum A, et al
    Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Eur J Dermatol. 2020 Dec 18. pii: ejd.2020.3910. doi: 10.1684/ejd.2020.3910.
    PubMed    
    
    
    November 2020
90. KIMURA R, Sugita K, Yamamoto O
    Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Eur J Dermatol. 2020 Nov 24. pii: ejd.2020.3904. doi: 10.1684/ejd.2020.3904.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypersensitivity Reaction is free of charge.